NCT05763472

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

Molecular Landscape Involved in the Onset of Breast Cancer in Patients With Germline BRCA-1/2 Mutations, During or After Therapy With Platinum-based Agents and/or PARP-inhibitors for Ovarian Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 10 (estimated)
• Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate, in patients with germline BRCA-1/2 mutations and breast cancer, arising during and / or after treatment with platinum-based chemotherapy and / or with PARP-inhibitors for ovarian cancer, the presence of molecular alterations potentially involved in the mechanisms of resistance to antineoplastic treatment on breast and ovarian tumor tissue.

Conditions

• BRCA-Associated Breast Carcinoma

Interventions

Type	Name	Description
GENETIC	Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).	Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.

Timeline

• Start date: 2022-03-01
• Primary completion: 2023-06-01
• Completion: 2023-06-01
• First posted: 2023-03-10
• Last updated: 2023-03-10

Locations

1 site across 1 country: Italy